



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		<b>Application Number</b>	10/817,312		
		<b>Filing Date</b>	April 1, 2004		
		<b>First Named Inventor</b>	Stephen S. Palmer		
		<b>Group Art Unit</b>			
		<b>Examiner Name</b>			
<b>Sheet</b>	1	<b>of</b>	13	<b>Attorney Docket Number</b>	05558.0011.NPUS04

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
<i>AD</i>	A1	2002/0103106 A1	08/01/2002	Palmer, et al	
<i>AD</i>	A2	2003/0018037 A1	01/23/2003	Simon Lempriere, et al.	
<i>AD</i>	A3	5,703,098	12/30/1997	Muller, et al.	
<i>AD</i>	A4	5,739,144	04/14/1998	Warrelow, et al.	
<i>AD</i>	A5	5,767,067	06/16/1998	Arpaia, et al.	
<i>AD</i>	A6	6,127,363	10/03/2000	Doherty, Jr., et al.	
<i>AD</i>	A7	6,624,181 B1	09/23/2003	Kilian, et al.	
<i>AD</i>	A8	6,649,633 B2	11/18/2003	Chambers, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
<i>AD</i>	B1	DE 1545687	08/07/1969			
	B2	DE 20208869	12/23/1970			
	B3	DE 2123328	12/02/1971			
	B4	DE 2315801	10/11/1973			
	B5	DE 2402908	07/24/1975			
	B6	DE 2413935	10/16/1975			
	B7	DE 3900233	07/20/1989			
	B8	EP 0103497	01/29/1986			
	B9	EP 0139464	01/02/2004			
	B10	EP 0158380	01/11/1989			
	B11	EP 0163965	11/08/1989			
	B12	EP 0335386	09/02/1992			
	B13	EP 0389282	02/20/2002			
	B14	EP 0393500	10/24/1990			
	B15	EP 0428302	09/24/1997			
	B16	EP 0435811	09/01/1993			
	B17	EP 0459505	10/02/1996			
<i>AD</i>	B18	EP 0470805	09/07/1994			
<b>Examiner Signature</b>	<i>[Signature]</i>			<b>Date Considered</b>	11/2/05	

\*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds codes of USPTO Patent Documents as [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Appeal to be  
missing  
from file.  
Initial  
considered  
of 5/04/05  
office Action  
in body of  
office action

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 13

## Complete if Known

Application Number	10/817,312
Filing Date	April 1, 2004
First Named Inventor	Stephen S. Palmer
Group Art Unit	1653
Examiner Name	A. Desai
Attorney Docket Number	05558.0011.NPUS04

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
AD	B19	EP 0490823	06/17/1992			
	B20	EP 0506194	08/21/1996			
	B21	EP 0510562	10/28/1992			
	B22	EP 0511865	11/04/1992			
	B23	EP 0527117	02/10/1993			
	B24	EP 0553174	08/04/1993			
	B25	EP 0557016	08/25/1993			
	B26	EP 0626939	12/07/1994			
	B27	EP 0664289	07/26/1995			
	B28	EP 0671389	09/13/1995			
	B29	EP 0685474	09/16/1998			
	B30	EP 0685475	01/13/1999			
	B31	EP 0685479	01/13/1999			
	B32	EP 0736532	05/15/2002			
	B33	EP 0738715	01/29/2003			
	B34	EP 0748805	04/08/1998			
	B35	EP 0763534	02/26/2003			
	B36	EP 0816357	01/09/2002			
	B37	EP 0819688	01/21/1998			
	B38	EP 0819689	01/21/1998			
	B39	EP 0832886	11/13/2002			
	B40	EP 0834508	08/16/2001			
	B41	EP 0848000	08/03/1983			
	B42	EP 0470805	09/07/1994			
	B43	EP 0103497	09/20/1989			
	B44	JP 92234389	08/24/1992			
	B45	JP 94329652	11/29/1994			
	B46	JP 95010875	01/13/1995			
	B47	JP 98072415	03/17/1998			

Examiner Signature	<i>AD</i>	Date Considered	11/2/05
--------------------	-----------	-----------------	---------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

See  
first  
sheet

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3

13

## Complete if Known

Application Number	10/817,312
Filing Date	April 1, 2004
First Named Inventor	Stephen S. Palmer
Group Art Unit	
Examiner Name	
Attorney Docket Number	05558.0011.NPUS04

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	B48	JP 98147585	06/02/1998			
	B49	WO 02/083239	10/24/2002	Ares Trading S.A.		
	B50	WO 02/083241	10/24/2002	Ares Trading S.A.		
	B51	WO 03/051344	06/26/2003	Applied Research Ssystems ARS Holding, N.V.		
	B52	WO 91/17991	11/28/1991	Byk'Gulden Lomberg Chemische Fabrik GMBH		
	B53	WO 92/00968	01/23/1992	Smith-Kline Beecham Corporation		
	B54	WO 92/12961	08/06/1992	Rhone Poulenc Rorer Limited		
	B55	WO 93/07124	04/15/1993	Eisai Co., Ltd.		
	B56	WO 93/07146	04/15/1993	Syntex Inc.		
	B57	WO 93/15044	08/05/1993	Smith-Kline Beecham Corporation		
	B58	WO 93/15045	08/05/1993	Smith-Kline Beecham Corporation		
	B59	WO 93/18024	09/16/1993	Rhone-Poulenc Rorer Limited		
	B60	WO 93/19068	09/30/1993	Syntex Inc.		
	B61	WO 93/19720	10/14/1993	Smith-Kline Beecham Corporation		
	B62	WO 93/19747	10/14/1993	Smith-Kline Beecham Corporation		
	B63	WO 93/19749	10/14/1993	Smith-Kline Beecham Corporation		

Examiner  
Signature

Date  
Considered

11/21/03


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

\*see  
first  
sheet

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4

13

## Complete if Known

Application Number	10/817,312
Filing Date	April 1, 2004
First Named Inventor	Stephen S. Palmer
Group Art Unit	
Examiner Name	
Attorney Docket Number	05558.0011.NPUS04

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
AD	B64	WO 93/19751	10/14/1993	Smith-Kline Beecham Corporation		
	B65	WO 93/25517	12/23/1993	Celltech Limited		
	B66	WO 94/02465	02/03/1994	Rhone-Poulenc Rorer Limited		
	B67	WO 94/12461	06/09/1994	Pfizer Inc.		
	B68	WO 94/20455	09/15/1994	Celltech Limited		
	B69	WO 94/22852	10/13/1994	Syntex Inc.		
	B70	WO 94/27947	12/08/1994	Rhone-Poulenc Rorer Limited		
	B71	WO 95/19978	07/27/1995	Laboratoires Glaxo S.A.		
	B72	WO 95/01338	01/12/1995	Byk Gulden Lomberg Chemische Fabrik GMBH		
	B73	WO 95/01980	01/19/1995	Pfizer Inc.		
↓	B74	WO 95/04045	02/09/1995	Rhone-Poulenc Rorer Limited		
	B75	WO 95/04046	02/09/1995	Rhone-Poulenc Rorer Limited		
	B76	WO 95/05113	02/23/1995	Block Medizintechnik GMBH		
	B77	WO 95/05386	02/23/1995	Smithkline Beechem Corporation		
	B78	WO 95/08534	03/30/1995	Glaxo Inc.		
	B79	WO 95/09623	04/13/1995	Smithkline Beechem Corporation		
	B80	WO 95/09624	04/13/1995	Smithkline Beechem Corporation		
	B81	WO 95/09627	04/13/1995	Smithkline Beechem Corporation		

Examiner  
Signature

Date  
Considered

11/21/05


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional): <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

see  
first  
sheet

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	5	13
-------	---	----

## Complete if Known

Application Number	10/817,312
Filing Date	April 1, 2004
First Named Inventor	Stephen S. Palmer
Group Art Unit	
Examiner Name	
Attorney Docket Number	05558.0011.NPUS04

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>2</sup> -Number <sup>4</sup> - Kind Code <sup>3</sup> (if known)				
AD	B82	WO 95/09836	04/13/1995	Smithkline Beechem Corporation		
	B83	WO 95/14667	06/01/1995	Pfizer, Inc.		
	B84	WO 95/14680	06/01/1995	Pfizer, Inc.		
	B85	WO 95/14681	06/01/1995	Pfizer, Inc.		
	B86	WO 95/17392	06/29/1995	Celltech Therapeutics Limited		
	B87	WO 95/17399	06/29/1995	Celltech Therapeutics Limited		
	B88	WO 95/19362	07/20/1995	Pfizer, Inc.		
	B89	WO 95/20578	08/03/1995	Rhone-Poulenc Rorer Limited		
	B90	WO 95/22520	08/24/1995	American Home Products Corporation		
	B91	WO 95/24381	09/14/1995	Smithkline Beechem Corporation		
	B92	WO 95/27692	10/19/1995	Smithkline Beechem Corporation		
	B93	WO 95/35281	12/28/1995	Celltech Therapeutics Limited		
	B94	WO 95/35283	12/28/1995	Celltech Therapeutics Limited		
	B95	WO 95/35284	12/28/1995	Celltech Therapeutics Limited		
↓	B96	WO 96/26940	09/06/1996	Kyowa Hakko Kogyo Co., Ltd.		
KO	B97	WO 96/00218	01/04/1996	Euro-Celtique, S.A.		

Examiner Signature		Date Considered	11/21/05
-----------------------	--	--------------------	----------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

See  
first  
sheet

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6

13

## Complete if Known

Application Number	10/817,312
Filing Date	April 1, 2004
First Named Inventor	Stephen S. Palmer
Group Art Unit	
Examiner Name	
Attorney Docket Number	05558.0011.NPUS04

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
AS	B98	WO 96/01825	01/25/1996	Fujisawa Pharmaceutical Co., Ltd.		
	B99	WO 96/03399	02/08/1996	Byk Gulden Lomberg Chemische Fabrik GMBH		
	B100	WO 96/06843	03/07/1996	Yamanouchi Pharmaceutical, Inc.		
	B101	WO 96/11690	04/25/1996	Institut de Recherche Jouveinal		
	B102	WO 96/11917	04/25/1996	Euro-Celtique, S.A.		
	B103	WO 96/12720	05/02/1996	Pfizer, Inc.		
	B104	WO 96/31486	10/10/1996	Janssen Pharmaceutica N.V.		
	B105	WO 96/31487	10/10/1996	Janssen Pharmaceutica N.V.		
	B106	WO 96/35683	11/14/1996	Nippon Kayaku Kabushiki Kaisha		
	B107	WO 96/36595	11/21/1996	Chiroscience Limited		
	B108	WO 96/36596	11/21/1996	Chiroscience Limited		
	B109	WO 96/36611	11/21/1996	Chiroscience Limited		
	B110	WO 96/36625	11/21/1996	Byk Gulden Lomberg Chemische Fabrik GMBH		
	B111	WO 96/36626	11/21/1996	Byk Gulden Lomberg Chemische Fabrik GMBH		
	B112	WO 96/36638	11/21/1996	Chiroscience Limited		
AD	B113	WO 96/38150	12/05/1996	Smithkline Beecham Corporation		

Examiner  
Signature

Date  
Considered

11/21/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

See note on first sheet

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)


Sheet 7 13

## **Complete if Known**

Application Number	10/817,312
Filing Date	April 1, 2004
First Named Inventor	Stephen S. Palmer
Group Art Unit	
Examiner Name	
Attorney Docket Number	05558.0011.NPUS04

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>	
A	B114	WO 96/39408	12/12/1996	Pfizer Inc.			
	B115	WO 96/40636	12/19/1996	Pfizer Inc.			
	B116	WO 97/15561	05/01/1997	Scherin Aktiengesellschaft			
	B117	WO 97/03967	02/06/1997	Rhone-Poulenc Rorer . Limited			
	B118	WO 9704779	02/13/1997	Chiroscience Limited			
	B119	WO 97/05105	02/13/1997	Pfizer Inc.			
	B120	WO 97/08143	03/06/1997	Celgene Corporation			
	B121	WO 97/09345	03/13/1997	St. Jude Children's Research Hospital			
	B122	WO 97/12895	04/10/1997	Japan Science and Technology Corporation			
	B123	WO 97/18208	05/22/1997	Sandoz-Patent-GMBH			
	B124	WO 97/19078	05/29/1997	Yamanouchi Pharmaceutical Co., Ltd.			
	B125	WO 97/20833	06/12/1997	Chiroscience Limited			
J	B126	WO 97/22585	06/26/1997	Merck Frosst Canada Inc.			
	B127	WO 97/22586	06/26/1997	Merck Frosst Canada Inc.			
	B128	WO 97/23457	07/03/1997	Celgene Corporation			
	B129	WO 97/23460	07/03/1997	Celltech Therapeutics Limited			
	B130	WO 97/23461	07/03/1997	Celltech Therapeutics Limited			
	B131	WO 97/24117	07/10/1997	Rhone-Poulenc Rorer Pharmaceuticals Inc.			
	JO	B132	WO 97/24355	07/10/1997	Fujisawa Pharmaceutical Co., Ltd.		

Examiner Signature		Date Considered	11/21/05
--------------------	-------------------------------------------------------------------------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

8 see  
note  
on  
first sheet

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8

13

## Complete if Known

Application Number	10/817,312
Filing Date	April 1, 2004
First Named Inventor	Stephen S. Palmer
Group Art Unit	
Examiner Name	
Attorney Docket Number	05558.0011.NPUS04

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
AD	B133	WO 97/25312	07/17/1997	Schering Aktiengesellschaft		
	B134	WO 97/28131	08/07/1997	Byk Gulden Lomberg Chemische Fabrik GMBH		
	B135	WO 97/30999	08/28/1997	Chiroscienc Limited		
	B136	WO 97/31000	08/28/1997	Chiroscience Limited		
	B137	WO 97/32853	09/12/1997	Novartis AG		
	B138	WO 97/35854	10/02/1997	Byk Gulden Lomberg Chemische Fabrik GMBH		
	B139	WO 97/36905	10/09/1997	Institut de Recherche Jouveinal		
	B140	WO 97/43288	11/20/1997	Byk Gulden Lomberg Chemische Fabrik GMBH.		
	B141	WO 97/44036	11/27/1997	Chiroscience Limited		
	B142	WO 97/44322	11/27/1997	Chiroscience Limited		
	B143	WO 97/47604	12/18/1997	Nikken Chemicals Co., Ltd.		
	B144	WO 97/48697	12/24/1997	Rhone-Poulen Rorer Limited		
	B145	WO 98/04534	05/02/1998	Nikken Chemicals Co., Ltd.		
	B146	WO 98/05327	02/12/1998	Rhone-Poulenc Rorer Pharmaceuticals Inc.		
	B147	WO 98/06692	02/19/1998	Celgene Corporation		
	B148	WO 98/06704	02/19/1998	Merck Patent GMBH		

Examiner Signature	<i>[Signature]</i>	Date Considered	11/21/05
--------------------	--------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

*sel*  
*rate*  
*on*  
*first sheet*



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9

13

## Complete if Known

Application Number	10/817,312
Filing Date	April 1, 2004
First Named Inventor	Stephen S. Palmer
Group Art Unit	
Examiner Name	
Attorney Docket Number	05558.0011.NPUS04

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
AD	B149	WO 98/07715	02/26/1998	Byk Gulden Lomberg Chemische Fabrik GMBH		
	B150	WO 98/08828	03/05/1998	Nikken Chemicals Co., Ltd.		
	B151	WO 98/08830	03/05/1998	Byk Gulden Lomberg Chemische Fabrik GMBH		
	B152	WO 98/08841	03/05/1998	Byk Gulden Lomberg Chemische Fabrik GMBH		
	B153	WO 98/08844	03/05/1998	Byk Gulden Lomberg Chemische Fabrik GMBH		
	B154	WO 98/09946	03/12/1998	Asta Medica Aktiengesellschaft		
	B155	WO 98/09961	03/12/1998	Pfizer Inc.		
	B156	WO 98/11113	03/19/1998	Euro-celtique, S.A.		
	B157	WO 98/14448	04/09/1998	Kyorin Pharmaceutical Co., Ltd.		
	B158	WO 98/18796	05/07/1998	Novartis AG		
AD	B159	WO 98/21208	05/22/1998	Byk Gulden Lomberg Chemische Fabrik GMBH		
	B160	WO 98/22453	05/28/1998	Byk Gulden Lomberg Chemische Fabrik GMBH		

Examiner Signature		Date Considered	11/2/08
--------------------	-------------------------------------------------------------------------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

use  
note  
on  
first  
sheet

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 10 13

## **Complete if Known**

Application Number	10/817,312
Filing Date	April 1, 2004
First Named Inventor	Stephen S. Palmer
Group Art Unit	
Examiner Name	
Attorney Docket Number	05558.0011.NPUS04

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
AD	B161	WO 98/31674	07/23/1998	Byk Gulden Lomberg Chemische Fabrik GMBH		
	B162	WO 98/40382	09/17/1998	Byk Gulden Lomberg Chemische Fabrik GMBH		
	B163	WO 98/45268	10/15/1998	Pfizer Inc.		
	B164	WO 98/55481	12/10/1998	Byk Gulden Lomberg Chemische Fabrik GMBH		
	B165	WO 98/56756	12/17/1998	Cheil Jedang Corporation		
	B166	WO 99/05111	02/04/1999	Byk Gulden Lomberg Chemische Fabrik GMBH		
	B167	WO 99/05112	02/04/1999	Byk Gulden Lomberg Chemische Fabrik GMBH		
	B168	WO 99/05113	02/04/1999	Byk Gulden Lomberg Chemische Fabrik GMBH		
	B169	WO 99/06404	02/11/1999	Almirall Prodesfarma		
	B170	WO 99/18095	04/15/1999	Merck Frosst Canada Inc.		
	B171	WO 99/31071	06/24/1999	Byk Gulden Lomberg Chemische Fabrik GMBH		
	B172	WO 99/31090	06/24/1999	Byk Gulden Lomberg Chemische Fabrik GMBH		

Examiner Signature		Date Considered	11/21/08
--------------------	-------------------------------------------------------------------------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

\* See  
w/c  
of  
first  
sheet

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 11 13

## Complete if Known

Application Number	10/817,312
Filing Date	April 1, 2004
First Named Inventor	Stephen S. Palmer
Group Art Unit	
Examiner Name	
Attorney Docket Number	05558.0011.NPUS04

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T <sup>2</sup>
AP	C1	Ahn, et al., "Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases With Oral Antihypertensive Activity," J. Med. Chem., Volume 40, pp. 2196-2210 (1997)	
	C2	Ashton, et al., "Selective Type IV Phosphodiesterase Inhibitors as Antiasthmatic Agents, etc." J. Med. Chem. Volume 37, pp. 1696-1703 (1994)	
	C3	Christensen, et al., "1,4-Cyclohexanecarboxylates: Potent and Selective Inhibitors of Phosphodiesterase 4 for the Treatment of Asthma," J. Med. Chem., Volume 41, pp. 821-835 (1998)	
	C4	Cleland, et al., "Emerging Protein Delivery Methods," Curr Opin Biotechnol., Volume 12, pp. 212-219 (2001)	
	C5	Corbin, et al., "S.H., Pharmacology of Phosphodiesterase-5 Inhibitors," International Journal of Clinical Practice, Volume 56 No. 6, pp. 453-459 (2002)	
	C6	Fares, et al., "Design a Long-Acting Follitropin Agonist by Fusing the C-Terminal Sequence of the Chorionic Gonadotropin $\beta$ subunit to the Follitropin $\beta$ Subunit," Proc. National Acad. Sci., Volume 89, pp. 4304-4308 (1992)	
	C7	Healy, et al., "Female Infertility: Causes and Treatment," Lancet, Vol. Volume 343, pp. 1539-1544 (1994)	
	C8	Jiang, et al., "Furoyl and Benzofuroyl Pyrroloquinolones as Potent and Selective PDE5 Inhibitors for Treatment of Erectile Dysfunction," J. Medical Chem., Vol. 46, pp. 441-444 (2003)	

Examiner Signature		Date Considered	11/01/05
--------------------	-------------------------------------------------------------------------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

see  
note  
on  
first  
sheet

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		<b>Application Number</b>	10/817,312
		<b>Filing Date</b>	April 1, 2004
		<b>First Named Inventor</b>	Stephen S. Palmer
		<b>Group Art Unit</b>	
		<b>Examiner Name</b>	
Sheet 12	13	<b>Attorney Docket Number</b>	05558.0011.NPUS04

<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T <sup>2</sup>
AD	C9	Karsa, et al., "Encapsulation and Controlled Release," The Royal Society of Chemistry (1993)	
	C10	Klein, et al., "Development and Characterization of a Long-Acting Recombinant hFSH Agonist," Human Reproduction, Vol. 18, No. 1, pp. 50-56 (2003)	
	C11	Klein, et al., "Pharmacokinetics and Pharmacodynamics of Single-Chain Recombinant Human Follicle-Stimulating Hormone Containing the Human Chorionic Gonadotropin Carboxyterminal Peptide in the Rhesus Monkey," Fertility and Sterility, Vol. 77, No. 6, pp. 1248-1255 (2002)	
	C12	LaPolt, et al., "Enhanced Stimulation of Follicle Maturation and Ovulatory Potential by Long Acting Follicle-Stimulating Hormone Agonists with Extended Carboxyl-Terminal Peptides," Endocrinology, Vol. 131, No. 6, p. 2514-2520 (1992)	
	C13	Luo, et al., "Novel Biomaterials for Drug Delivery," Expert Opinion Ther. Patents, Volume 11, pp. 1395-1410 (2001)	
	C14	Matzuk, et al., "The Biological Role of the Carboxyl-Terminal Extension of Human Chorionic Gonadotropin $\beta$ -Subunit," Endocrinology, Vol. 126, No. 1, pp. 376-383 (1990)	
	C15	Rotella, et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 Inhibitors as Potential Agents for Treatment of Erectile Dysfunction," J. Med. Chem, Vol. 43, pp. 1257-1263 (2000)	
AD	C16	Terrett, et al., "Sildenafil (Viagra <sup>TM</sup> ), A Potent and Selective Inhibitor of Type 5 CGMP Phosphodiesterase with Utility For the Treatment of Male Erectile Dysfunction," Bioorganic and Medicinal Chemistry Letters, Vol. 6, No. 15, pp. 1819-1824 (1996)	

<b>Examiner Signature</b>	<i>AD</i>	<b>Date Considered</b>	11/21/05
---------------------------	-----------	------------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


*see note on first sheet of IDS*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/817,312
		<b>Filing Date</b>	April 1, 2004
		<b>First Named Inventor</b>	Stephen S. Palmer
		<b>Group Art Unit</b>	
		<b>Examiner Name</b>	
Use as many sheets as necessary)		<b>Attorney Docket Number</b>	05558.0011.NPUS04
Sheet	13	13	

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T <sup>2</sup>
AD	C17	Thompson, et al., "Assay of Cyclic Nucleotide Phosphodiesterase and Resolution of Multiple Molecular Forms of the Enzyme," Advances in Cyclic Nucleotide Research, Vol. 10, pp. 69-92 (1979)	
	C18	Wiersma, et al., "Phosphodiesterase 3 Inhibitors Suppress Oocyte Maturation and Consequent Pregnancy Without Affecting Ovulation and Cyclicity in Rodents," J. Clin. Invest., Vol. 102, No. 3, pp. 532-537 (1998)	
	C19	Yacobi, et al., 1998, Oral Sustained Release Formulations: Design and Evaluation, Eva Halperin-Walega (Editor), 1st Ed.; Pergamon Press (1998)	
	C20	Physician's Desk Reference, PDR™, 57 <sup>th</sup> Ed. pages 2653-2656 (2003)	
	C21	Physician's Desk Reference, PDR™, 52 <sup>nd</sup> Ed. pages 1949-1951 (1998)	
	C22	Physician's Desk Reference, PDR™, 52 <sup>nd</sup> Ed. Pages 2771-2773 (1998)	
	C23	Physician's Desk Reference, PDR™, 52 <sup>nd</sup> Ed. Pages 2773-2775 (1998)	
	C24	Physician's Desk Reference, PDR™, 57 <sup>th</sup> Ed. pages 2401 (2003)	
	C25	Physician's Desk Reference, PDR™, 57 <sup>th</sup> Ed. pages 2994 (2003)	
	C26	Physician's Desk Reference, PDR™, 57 <sup>th</sup> Ed. pages 695 (2003)	
K	C27	Physician's Desk Reference, PDR™, 57 <sup>th</sup> Ed. pages 1324-1325 (2003)	
	C28	Physician's Desk Reference, PDR™, 57 <sup>th</sup> Ed. pages 1325-1327 (2003)	
	C29	Physician's Desk Reference, PDR™, 57 <sup>th</sup> Ed. pages 3119-3121 (2003)	
	C30	Physician's Desk Reference, PDR™, 57 <sup>th</sup> Ed. pages 3124-3128 (2003)	

<b>Examiner Signature</b>		<b>Date Considered</b>	11/2/03
---------------------------	-------------------------------------------------------------------------------------	------------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

see  
note  
on  
first  
sheet

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/817,312
				Filing Date	April 1, 2004
				First Named Inventor	Stephen S. Palmer
				Group Art Unit	1653
				Examiner Name	Anand U. Desai, Ph.D.
				Attorney Docket Number	05558.0011.NPSU04
Sheet	1	of	1		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Tr
		Country Code <sup>2</sup> -Number <sup>4</sup> - Kind Code <sup>3</sup> (if known)				
	B1					
	B2					
	B3					
	B4					


Examiner Signature		Date Considered	11/21/03
-----------------------	-------------------------------------------------------------------------------------	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.  
DM US8124836.v1

see  
nge  
on  
first  
sheet  
of  
8/6/05  
JDS

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		<b>Application Number</b>	10/817,312
		<b>Filing Date</b>	April 1, 2004
		<b>First Named Inventor</b>	Stephen S. Palmer
		<b>Group Art Unit</b>	1653
		<b>Examiner Name</b>	Anand U Desai, Ph.D.
Sheet 1 of 1		<b>Attorney Docket Number</b>	05558.0011.NPUS04

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T <sup>2</sup>
AD	C31	International Search Report from PCT/US2004/010346 dated October 26, 2004	

<b>Examiner Signature</b>		<b>Date Considered</b>	11/21/05
---------------------------	--	------------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

\* see  
note  
on  
first  
sheet  
IDS  
8/6/05